Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|September 19, 2016
When Should Patients Switch from Statins to PCSK9 Inhibitors?
Author(s)Lauren Santye, Assistant Editor
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School, discusses the treatment switch from statins to PCSK9 inhibitors in patients with high cholesterol.
Advertisement
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School, discusses the treatment switch from statins to PCSK9 inhibitors in patients with high cholesterol.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5